3 withdrawn, 2 completed. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Withdrawn 3, Completed 2 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Stage IV Fallopian Tube Cancer: new trials by email Literature Review of Stage IV Fallopian Tube Cancer trials Research Report on Stage IV Fallopian Tube Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2017-12-08 | 2018-05-01 | |
| Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis - Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor | Phase 1 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2015-06-01 | 2016-02-17 | |
| Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, IDO1 inhibitor INCB024360, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-12-01 | 2013-12-18 | |
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 | Completed | Roswell Park Cancer Institute | 7 | 2012-08-20 | 2020-03-27 |
| Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine - Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 1 | Completed | Mayo Clinic | 24 | 2012-07-24 | 2024-08-21 |
Fallopian Tube Neoplasms (5) · Ovarian Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Breast Neoplasms (1)
Adnexal Diseases (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Fallopian Tube Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Gonadal Disorders (5) · Neoplasms (5) · Neoplasms by Site (5) · Ovarian Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5)
Sirolimus (2) · sargramostim (2) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · aldesleukin (1) · epacadostat (1)
Roswell Park Cancer Institute (3) · Barbara Ann Karmanos Cancer Institute (1) · Mayo Clinic (1)
United States (3)
Kunle Odunsi (3) · Lawrence Lum (1) · Matthew S. Block, M.D., Ph.D. (1)
P30CA016056 (2), P30CA022453 (1), R01CA158318 (1)